Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
143.9 USD | -2.31% | -2.29% | +22.08% |
May. 29 | BofA Securities Adjusts Crane Price Target to $165 From $140, Maintains Buy Rating | MT |
May. 27 | CR Double-Crane Pharmaceutical's Unit Gets Nod for Phloroglucinol Injection | MT |
Financials (USD)
Sales 2024 * | 2.31B | Sales 2025 * | 2.47B | Capitalization | 8.42B |
---|---|---|---|---|---|
Net income 2024 * | 282M | Net income 2025 * | 332M | EV / Sales 2024 * | 3.64 x |
Net cash position 2024 * | 37.28M | Net cash position 2025 * | 376M | EV / Sales 2025 * | 3.26 x |
P/E ratio 2024 * |
30.3
x | P/E ratio 2025 * |
25.6
x | Employees | 7,300 |
Yield 2024 * |
0.55% | Yield 2025 * |
0.62% | Free-Float | 85.42% |
Latest transcript on Crane Company
1 day | +2.98% | ||
1 week | +2.59% | ||
Current month | -1.17% | ||
1 month | +3.06% | ||
3 months | +18.58% | ||
6 months | +40.19% | ||
Current year | +24.71% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 746 M€ | -.--% | - | |
0.04% | 20 M€ | -.--% | - | |
0.00% | 34 M€ | +4.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 144.2 | -2.11% | 32 959 |
24-06-05 | 147.3 | +2.98% | 176,946 |
24-06-04 | 143.1 | -1.94% | 192,939 |
24-06-03 | 145.9 | -2.13% | 168,941 |
24-05-31 | 149.1 | +1.00% | 276,248 |
Delayed Quote Nyse, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.71% | 8.42B | |
-16.94% | 12.49B | |
-7.82% | 6.41B | |
+42.14% | 2.07B | |
+5.58% | 1.59B | |
+11.55% | 860M | |
+3.43% | 866M | |
-7.13% | 638M | |
-14.28% | 610M | |
-27.32% | 370M |
- Stock Market
- Equities
- CR Stock